Maegim한국어

옵티팜

153710KOSDAQSector: Pharma & Biotech
₩4,750 0.31%Market cap ₩69.7BAs of Jul 21, 2026 close · updated once daily
C
Grade C45.2 ptsTop 62% of 2,523 stocks
Financial strength
41.2
Growth momentum
62.5
Price attractiveness
37.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

41.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
60.5%
Below median · Top 56.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
120.7%
Below median · Top 67.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-10.8%
Below median · Top 55.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-9.8%
Below median · Top 55.1% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

62.5
How much did revenue grow in a year?
Revenue growth (YoY)
13.8%
Above median · Top 32.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
11.8%
Above median · Top 27.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
1.5%
Below median · Top 53.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
28.5%
Above median · Top 36.8% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

37.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 57.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.74x
Below median · Top 67.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15